Routine laboratory screening among newly admitted psychiatric patients: Is it worthwhile?

Psychiatric Services

Volumn 58, Issue 12, 2007, Pages 1602-1605

  Arce Cordon, Rosario ^a   Perez Rodriguez, Maria M ^c   Baca Baldomero, Enrique ^a,b   Oquendo, Maria A ^d   Baca Garcia, Enrique ^d,e  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FREE THYROXINE INDEX; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT;

EID: 38049016532     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2007.58.12.1602     Document Type: Article

References (15)

1. Gregory RJ, Nihalani ND, Rodriguez E: Medical screening in the emergency department for psychiatric admissions: a procedural analysis. General Hospital Psychiatry 26:405-410, 2004
2. Allen MH, Forster P, Zealberg J, et al: Report and Recommendations Regarding Psychiatric Emergency and Crisis Services: A Review and Model Program Descriptions. Arlington, Va, American Psychiatric Association, APA Task Force on Psychiatric Emergency Services, 2002. Available at www.psych.org/edu/otherres/ libarchives/archives/tfr/tfr200201.pdf
3. Vergare MJ, Binder RL, Cook IA, et al: Practice Guideline for the Psychiatric Evaluation of Adults, 2nd ed. Arlington, Va, American Psychiatric Association, 2006. Available at www.psych.org/psychpract/ treatg/pg/ PsychEval2ePG04-28-06.pdf
4. Purchasing Power Parity 2000. Geneva, World Health Organization. Available at www.who.int/choice/costs/ppp/en
5. Bender R: Calculating confidence intervals for the number needed to treat. Controlled Clinical Trials 22:102-110, 2001
6. Grimes DA, Schulz KF: Uses and abuses of screening tests. Lancet 359:881-884, 2002
7. De Hert M, Van Winkel R, Van Eyck D, et al: Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health 2:14, 2006
8. Schillerstrom TL, Schillerstrom JE, Taylor SE: Laboratory findings in emergently medicated psychiatry patients. General Hospital Psychiatry 26:411-414, 2004
9. Heiskanen TH, Niskanen LK, Hintikka JJ, et al: Metabolic syndrome and depression: a cross-sectional analysis. Journal of Clinical Psychiatry 67:1422-1427, 2006
10. Lester D: Serum cholesterol levels and suicide: a meta-analysis. Suicide and Life-Threatening Behavior 32:333-336, 2002
11. Gabriel A: Changes in plasma cholesterol in mood disorder patients: does treatment make a difference? Journal of Affective Disorders 99:273-278, 2007
12. Cole DP, Thase ME, Mallinger AG, et al: Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. American Journal of Psychiatry 159:116-121, 2002
13. Abulseoud O, Sane N, Cozzolino A, et al: Free T4 index and clinical outcome in patients with depression. Journal of Affective Disorders 100:271-277, 2007
14. Hickie I, Bennett B, Mitchell P, et al: Clinical and subclinical hypothyroidism in patients with chronic and treatment-resistant depression. Australian and New Zealand Journal of Psychiatry 30:246-252, 1996
15. Rembold CM: Number needed to screen: development of a statistic for disease screening. British Medical Journal 317: 307-312, 1998